PBYI at a glance
PUMA BIOTECHNOLOGY, INC. (PBYI, SEC CIK 1401667) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), PUMA BIOTECHNOLOGY, INC. (PBYI) reported revenue of $228.4 million (down 0.9% from FY2024) and net income of $31.1 million. Diluted EPS was $0.61.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding PUMA BIOTECHNOLOGY, INC. (PBYI) shares worth $135.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Cesano Alessandra on September 14, 2026 of 62,150 shares at $9.12 per share.
- In the last 90 days, PBYI insiders reported 0 open-market purchases ($0) and 2 open-market sales ($612K) on Form 4, a net sale of $612K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $228.4M
- −0.9% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$612K
- 13F holders
- 26 funds
- $135.8M · −1 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No risk-factors section provided; supplied text covers Items 2–6 and signatures
- Newly adopted Rule 10b5-1 plans allow directors to sell up to 117,843 shares
- Note Purchase Agreement amended April 16, 2026 with Athyrium Opportunities IV Co-Invest 1 LP
AI summary of the PBYI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, furnished through Exhibit 99.1
- Exhibit 99.1 contains the substantive financial results and management commentary for investor review
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders re-elected all eight director nominees for one-year terms through the 2027 annual meeting
- KPMG LLP ratified as independent auditor for fiscal 2026, with 42,612,940 votes supporting
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1 contains detailed operating and financial results
AI summaries of PBYI 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PBYI
Don't miss the next PBYI filing
- Alerts as it files. A push when PBYI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PBYI, by share count.
- Ask anything. An AI agent that reads every PBYI filing and answers with sources.
PBYI alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Cesano Alessandra | M | Sep 14, 2026 | 50,000 | - |
| Cesano Alessandra | M | Sep 14, 2026 | 50,000 | $2.93 |
| Cesano Alessandra | Sell | Sep 14, 2026 | 62,150 | $9.12 |
| WILSON TROY EDWARD | Sell | Sep 14, 2026 | 5,000 | $9.10 |
| NOUGUES MAXIMO F | Sell | Jul 6, 2026 | 9,386 | $8.26 |
| HUNT DOUGLAS M | Sell | Jul 6, 2026 | 8,460 | $8.26 |
| AUERBACH ALAN H | Sell | Jul 6, 2026 | 44,058 | $8.26 |
| Dorval Allison | Sell | Jun 12, 2026 | 11,610 | $7.20 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $230.5M | $228.4M |
| Operating Income | - | $31.0M | $37.3M |
| Net Income | $21.6M | $30.3M | $31.1M |
| Op. Margin | - | 13.4% | 16.3% |
| Net Margin | - | 13.1% | 13.6% |
| Balance Sheet | |||
| Total Assets | - | $213.3M | $216.3M |
| Equity | $53.4M | $92.1M | $130.3M |
| ROE | 40.4% | 32.9% | 23.9% |
| Per Share | |||
| EPS | $0.45 | $0.62 | $0.61 |
| Cash Flow | |||
| Operating CF | - | $38.9M | $41.8M |
| CapEx | $140K | $56K | $71K |
Source: XBRL data in PUMA BIOTECHNOLOGY, INC. (PBYI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate PBYI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $135.8M |
| Q1 2026 | 27 | $109.9M |
| Q4 2025 | 24 | $95.1M |
| Q3 2025 | 26 | $76.9M |
| Q2 2025 | 24 | $51.3M |
| Q1 2025 | 21 | $33.2M |
| Q4 2024 | 17 | $31.5M |
| Q3 2024 | 14 | $17.5M |
- Invesco Ltd+206.0K (+217%)
- BlackRock+205.8K (+6%)
- Two Sigma Investments+127.6K (+981%)
- Vanguard Portfolio Management LLC+91.0K (+5%)
- Dimensional Fund Advisors+81.9K (+6%)
- Millennium Management−875.3K (-59%)
- Renaissance Technologies LLC−106.2K (-5%)
- Morgan Stanley−94.1K (-26%)
- AQR Capital Management−75.0K (-9%)
- Franklin Resources−43.4K (-20%)
- Citadel Advisors LLC−30.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 179 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PBYI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 26, 2026 | - | Analysis | - |
| 4 | Feb 20, 2026 | - | - | |
| 4 | Feb 20, 2026 | - | - | |
| 4 | Feb 20, 2026 | - | - | |
| 4 | Jan 8, 2026 | - | - | |
| 4 | Jan 8, 2026 | - | - | |
| 4 | Jan 8, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PBYI SEC filings: frequently asked questions
Are PBYI insiders buying or selling?
In the last 90 days, PUMA BIOTECHNOLOGY, INC. (PBYI) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $612,494 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PBYI stock?
As of June 30, 2026, the largest PUMA BIOTECHNOLOGY, INC. (PBYI) holders among the 13F filers tracked by SignalX were BlackRock ($30.9 million), Renaissance Technologies LLC ($14.9 million), Vanguard Capital Management LLC ($14.9 million), Vanguard Portfolio Management LLC ($14.8 million), Dimensional Fund Advisors ($12.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PBYI's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), PUMA BIOTECHNOLOGY, INC. (PBYI) reported revenue of $228.4 million (down 0.9% from FY2024) and net income of $31.1 million. Diluted EPS was $0.61. The figures come from the XBRL data in the 10-K.
What did PBYI report in its latest 8-K?
PUMA BIOTECHNOLOGY, INC. (PBYI) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026, furnished through Exhibit 99.1.
What are the latest PBYI SEC filings?
PUMA BIOTECHNOLOGY, INC. (PBYI) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on September 16, 2026.
What is PBYI's SEC CIK number?
PUMA BIOTECHNOLOGY, INC. (PBYI)'s SEC Central Index Key (CIK) is 1401667. EDGAR lists every PBYI filing under that number.
Ask anything about PBYI
The research agent reads PBYI's filings, financials, insider trades and 13F holders, then answers with sources.